Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NR2C2 | P49116 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | TAB1 | Q15750 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | RAF1 | P04049 | 4/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546095 | 0.90 | RAF1 (0.51) | NPC1RAB9AKMT2AKDRNFKB1 | |
| SCHEMBL5419991 | 0.90 | RAF1 (0.52) | NPC1RAB9AKDRNFKB1NR2C2 | |
| SCHEMBL5420002 | 0.90 | KDR (0.61) | NPC1RAB9AKMT2AKDRNFKB1 | |
| SCHEMBL5425487 | 0.89 | RAB9A (0.54) | NPC1RAB9AKDRNFKB1NR2C2 | |
| SCHEMBL5426028 | 0.88 | NPC1 (0.55) | NPC1RAB9AKMT2AKDRNFKB1 | |
| SCHEMBL5423665 | 0.87 | KDR (0.58) | KMT2AKDRNFKB1NR2C2NFKB2 | |
| SCHEMBL5421103 | 0.87 | KDR (0.49) | NPC1RAB9AKMT2AKDRNFKB1 | |
| SCHEMBL546094 | 0.87 | RAF1 (0.65) | KMT2AKDRNFKB1NR2C2NFKB2 | |
| SCHEMBL5428333 | 0.87 | KDR (0.49) | NPC1RAB9AKDRNFKB1NR2C2 | |
| SCHEMBL5418789 | 0.87 | NPC1 (0.56) | NPC1RAB9AKMT2AKDRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | NPC1 1541/4885RAB9A 2160/4885KMT2A 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.